Investor Presentation Q1 2023
9
Investor presentation
First three months of 2023
Novo NordiskⓇ
Obesity care sales grew by 124% in the first quarter of 2023
mainly driven by the US following relaunch of Wegovy
NN sales and volume BAOM market growth
within Obesity care
Branded AOM TRX in the US²
DKK billion
TRX count ('000s)
10
140
55%1
84%1
124%1
75%
120
8
6
4
2
54%
55%
100
80
35%
60
40
15%
20
0
-5%
0
2021
2022
2023
June
2021
IO
INAO
- BAOM Market growth (RHS)
SaxendaⓇ
INN sales growth at CER
Branded AOM market
1Annual growth at CER. Each TRX data points represents one week of data; 2IQVIA weekly, 14 Apr 2023
131
109
•
14
Apr
2023
-WegovyⓇ
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
The US
•
Commercial relaunch in January 2023
Broad commercial formulary access
To safeguard continuity of care, the
supply of the lower WegovyⓇ dose
strenghts in the US will be reduced
temporarily
International Operations
•
WegovyⓇ launched in Denmark and
Norway
Gradual roll-out in IO
NAO: North America operations; IO: International operations; RHS: Right-hand side axis; Rx: Prescriptions; AOM: Anti-Obesity Medications (includes Wegovy®, SaxendaⓇ, Qsymia, Belviq and Contrave); CER: Constant exchange rates
Note: Sales growth at constant exchange rates. 54% volume growth for Global BAOM market growth refers to moving annual total.View entire presentation